Reference
- AGARWALA, S. S., REYDERMAN, L., STATKEVICH, P., FRAAS, U., TAGLIETTI, M., STOVER, L. L. and KIRKWOOD, J. M., 1998, Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma. In European Society of Medical Oncology, 23rd Congress (abst).
- BAKER, S. D., WIRTH, M., STATKEVICH, P., REIDENBERG, P., ALTON, K., SARTORIUS, S. E., DUGAN, M., CUTLER, D. L., BATRA, V., GROCHOW, L. B., DONEHOWER, R. C. and ROWINSKY, E. K., 1999, Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clinical Cancer Research, 5, 309–317.
- CARTER, C. A., WAUD, W. R. and PLOWMAN, J., 1994, Responses of human melanoma, ovarian, and colon tumor xenografts in nude mice to oral temozolomide. Proceedings of the American Association of the Cancer Research, 35, 297 (A1769).
- DENNY, B. J., WHEELHOUSE, R. T., STEVENS, F. G., TSANG, L. H. and SLACK, J. A., 1994, NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide an its interaction with DNA. Biochemistry, 33, 9045–9051.
- FREIREICH, E. J., GEHAN, E. A., RALL, D. P., SCHMIDT, L. H. and SKIPPER, H. E., 1996, Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemotherapy Reports, 50, 219–244.
- GIBALDI, M. and PERRIER, D., 1982, Pharmacokinetics, 2nd edn (New York: Marcel Dekker), pp. 409–417.
- HORGAN, C. M. T. and TISDALE, M. J., 1985, Antitumor imidazotetrazines. VIII. Uptake and decomposition of a novel antitumor agent Mitozolomide (CCCRG 81010; M and B 39656, NSC 353451) in TLX5 mouse lymphoma in vitro. Biochemical Pharmacology, 34, 217–221.
- SCHULMAN, M. P. and BUCHANAN, J. M., 1952, Biosynthesis of the purines II. Metabolism of 4-amino-5-imidazolecarboxamide in pigeon liver. Journal of Biological Chemistry, 196, 513–526.
- SLACK, J. A., GODDARD, C., STEVENS, M. F. G., BAIG, G. U. and GRIFFIN, M. J., 1986, The analysis and murine pharmacokinetics of a new antitumor agent: CCRG 81045. Journal of Pharmacy and Pharmacology, 38, 63P.
- STEVENS, M. F. G., HICKMAN, J. A., LANGDON, S. P., CHUBB, D., VICKERS, L., STONE, R., BAIG, G., GODDARD, C., GIBSON, N. W., SLACK, J. A., NEWTON, C. and LUNT, E., 1987, Antitumor activity and pharmacokinetics in mice of 8-carbamoy1-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831) a novel drug with potential as an alternative dacarbazine. Cancer Research, 47, 5846–5852.
- STUPP, R., OSTERMANN, S., LEYVRAZ, S., CSAJKA, C. and BUCLIN, L. A., 2001, Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proceedings of ASCO, 20, 59 (abst 232).
- TSANG, L. L. H., QUATERMAN, C. P., GESCHER, A. and SLACK, J. A., 1991, Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-l-yl)imidazole-4-carboxamide. Cancer Chemotherapy and Pharmacology, 27, 342–346.
- WELCH, R. M., BROWN, A., RAVITCH, J. and DAHL, R., 1995, The in vitro degradation of cisatracurium the R, cis-R-isomer of atracurium, in human and rat plasma. Clinical Pharmacology and Therapeutics; 58, 132–142.
- WHEELHOUSE, R. T. and STEVENS, M. F. G., 1993, Decomposition of the antitumor drug temozolomide in deutirated phosphate buffer: methyl group transfer is accompanied by deuterium exchange. Journal of Chemical Society and Chemical Communications, 15, 1177–1178.